Why Did Welch Group LLC Reduce Its Stake in Pfizer (NYSE:PFE)?

2 min read | February 04, 2025 07:40 AM PST | By Team Kalkine Media

Why Did Welch Group LLC Reduce Its Stake in Pfizer (NYSE:PFE)? — Image source: Shutterstock

Welch Group LLC Adjusts Position in Pfizer

Welch Group LLC decreased its stake in Pfizer (NYSE:PFE) during the fourth quarter, as stated in a recent filing with the SEC. The fund sold 559,366 shares, reducing its total to 1,032,856 shares. Following this adjustment, Welch Group LLC’s remaining holdings in the biopharmaceutical company were valued at $27,288,000.

Institutional Interest in Pfizer

Several large financial firms have made changes to their Pfizer holdings in recent months. State Street Corp increased its position by 1.2% in the third quarter, bringing its total to 290,460,600 shares, valued at $8,405,930,000. Additionally, Charles Schwab Investment Management raised its stake by 11%, acquiring 12,864,343 additional shares, bringing its total to 130,143,942 shares, worth $3,766,366,000.

Geode Capital and UBS AM Expand Their Holdings

Geode Capital Management also increased its Pfizer position by 1.6% in the third quarter. The firm now owns 117,666,245 shares, valued at $3,392,342,000. Meanwhile, UBS AM, a division of UBS Asset Management Americas, expanded its stake by 22.4%, purchasing 6,977,587 additional shares, bringing its total to 38,068,879 shares, valued at $1,101,713,000.

Swiss National Bank's Involvement

Swiss National Bank made a smaller adjustment, increasing its stake by 0.6%. The institution now holds 16,819,712 shares of Pfizer, valued at $486,762,000, after adding 100,900 shares in the last quarter.

Institutional Ownership Trends

Institutional investors and hedge funds collectively own 68.36% of Pfizer. These organizations frequently adjust their holdings based on market conditions and company performance. The continued involvement of major financial firms suggests that Pfizer remains a focus within the biopharmaceutical sector.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.